IN TWO COUNTRIES, regulators concerned about a possible monopoly of technologies and instruments used in human gene sequencing apparently were a major reason why the $1.2 billion acquisition of Pacific Biosciences by Illumina Corporation will not happen. The two companies announced the termination of the transaction just weeks after the Federal Trade Commission (FTC) ruled the …
Anti-Trust Regulators Opposed Illumina, Pacific Bioscience Deal Read More »